

Research Xchange Forum 2018

Insights | Translation | Solutions
Trends and Challenges in Regenerative Medicine & Cell Therapy



March 20 – 21, 2018 Sartorius Goettingen, Germany





What to expect

Learn about the latest Insights in regenerative medicine and cell therapy and exchange ideas as to their Translation into viable Solutions.

Our Research Xchange Forum brings together academic and industry experts to foster exchange and to stimulate dialog about the next generation of interdisciplinary research. Establish new contacts and explore the potential for collaborations with like-minded companies and academic professionals to gain a better understanding of their processes, workflows and challenges.

Deepen your discussions during a joint gala dinner and be there when the winner and the 3 finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy" receive their awards. Winner: U.S. \$25,000 + publication in Science print and online; 3 finalists: U.S. \$5,000 per winner + publication in Science online.

We look forward to seeing you at our Research Xchange Forum.

Highlights

- Keynote lectures by the winner and lectures by the 3 finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy", including a speech by Science editor Dr. Priscilla N. Kelly
- Keynote lectures on cellular immunotherapy by industry experts
- Inspirational speech by the Nobel Prize laureate of 2014 in chemistry Prof. Dr. Stefan W. Hell
- Panel discussion with stakeholders from industry and academia including Science editor Dr. Priscilla N. Kelly
- Gala dinner and award ceremony for the exceptional scientists receiving "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy"
- Thought-provoking dialog and networking opportunities with academic and industry experts
- Exclusive inside view into the work processes of Sartorius during an optional plant tour









Speaker line-up*

Editor

Guest Contributors



Dr. Priscilla N. Kelly, Washington DC, USA AAAS/Science

Topic: "How to publish in *Science*"



© Peter Badge/ Typos1 in cop. with Foundation Lindau Nobel Laureate Meetings – all rights reserved 2017.

Prof. Dr. Stefan W. Hell, Goettingen, Germany

Max Planck Institute for Biophysical Chemistry Managing Director and Nobel Prize laureate of 2014 in chemistry

Topic: "How to win a Nobel Prize"

Academic Speakers

Keynote lecture by the winner and lectures by the 3 finalists of "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy"



Prof. Dr. Stefan Wölfl Heidelberg, Germany

University of Heidelberg, Institute for Pharmacy and molecular Biotechnology

Topic: Small molecules to enable, faciliate and improve iPSC generation and cell reprogramming

Overview: The generation of patient specific specialized cell-types is a major task in regenerative medicine. Despite the success of genetic reprogramming protocols, it is still a challenge to generate, cultivate and expand patient specific induced pluripotent stem cells (iPSCs). The generation of iPSCs requires the expression of specific

transcription factors, expression of which is maintained to conserve the pluripotent state. For reprogramming these factors are inhibited and tissue specific sets of gene expression are induced. We focus on the development of chemical compounds to replace genetic reprogramming and e.g. have identified Oct4 inducing small molecules. Although we cannot yet fully replace genetic reprogramming factors, our small molecules improve reprogramming efficiency, overcome reprogramming resistance and improve cultivation of iPSCs for reprogramming.

Speaker line-up*

Industry Speakers



Dr. Ulf Geumann, Munich, Germany

apceth Biopharma GmbH, Group Leader Preclinical Development

Topic: Mesenchymal stem cells in immunotherapy

Overview: apceth is harnessing the potential of mesenchymal stem cells (MSC), in which the mechanism of therapeutic effects are very different from that of CAR-T cells. The aim is to provide innovative cell-based gene therapies for the treatment of major indications such as cancer, chronic lung and kidney diseases and for immunomodulation.

apceth has created its allogenic therapeutic platform based entirely on the genetic engineering of MSC isolated from healthy donors.



Francesca Bellintani, Milan, Italy

MolMed, Vector Downstream Process Development Manager

Topic: Retroviral and lentiviral production: development and scaling up of upstream and downstream process steps

Overview: MolMed has implemented a large-scale process to meet the increasing demand for clinical and commercial grade vector production. There is a special focus on identification of challenges in the downstream | purification strategy to ensure efficient contaminant removal and preservation of viral infectivity.



Dr. Thierry Wurch Suresnes, France

Servier, Director of External Studies in Immuno-oncology

Topic: Allogenic approach developed by Servier and the preclinical data of UCART19

Overview: Servier is applying the Cellectis' TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, "off-the-shelf" T cell based medicinal product. UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies. It is currently being evaluated in a phase 1 clinical trials in relapsed | refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead).



Dr. Nina G. Bauer Basel. Switzerland

Lonza Assoc. Director of Commercial Development, Autologous Cell Therapies

Topic: Manufacturing strategies for patient scale cell therapies

Overview: The "Future Technologies" husiness area under the Pharma & Riotech division of Lonza has a focus on personalized medicine & cell therapy. One of the major challenges in these fields is the production of the patient-specific and patient-scale CAR-T cells or stem cells for treatment. Lonza has partnered with Octane on the Octane Cocoon[™] platform, which offers a ground-breaking innovation to address this challenge. Unlike current, labor-intensive production methods, this platform has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up.

Agenda

Tuesday, March 20

Chair: Ruth McDermott

09:40	Transfer to Sartorius College (from hotel)	
10:00 – 11:00	Registration	
11:00 – 11:30	Welcome & Introduction	Gerry MacKay, Sartorius, Germany Member of the Group Executive Commitee and Executive Vice President LPS Marketing Sales Services
11:30 – 12:00	Inspirational speech: How to win a Nobel Prize	Prof. Dr. Stefan Hell, Max Planck Institute for Biophysical Chemistry, Germany Managing Director and Nobel Prize laureate of 2014 in chemistry
12:00 – 12:30	How to publish in Science	Dr. Priscilla N. Kelly, AAAS Science, USA Editor
12:30 - 13:15	Lunch break Application Session	
13:15 – 14:00	Keynote presentation	Sartorius & Science Prize Winner
14:00 - 14:30	Lecture	Sartorius & Science Prize Finalist 1
14:30 – 15:00	Coffee break	
15:00 – 15:30	Lecture	Sartorius & Science Prize Finalist 2
15:30 – 16:00	Lecture	Sartorius & Science Prize Finalist 3

16:00 – 17:00	Panel Discussion In search of excellence -Scientific publications in the 21st century	Moderation:	
		Dr. Reinhard Baumfalk, Sartorius, Germany Vice President R&D Instrumentation & Control	
		Participants:	
		Prof. Dr. Stefan Hell, Dr. Priscilla N. Kelly, Dr. Ulf Geumann	
17:00 – 17:15	Sum up & Closing		
17:20	Transfer to hotel (from Sartorius College)		
18:15	Transfer to award ceremony (from hotel)		
18:30 – 23:30	Award ceremony		

23:30

Transfer to hotel

Agenda

Wednesday, March 21

Chair: Del Trezise

08:15	Transfer to Sartorius College Sartorius Trainingscenter (from hotel)			
08:30 - 10:00	Optional Plant Tour (Sartorius College)			
	or			
	Upscaling Lab Demonstration Tour			
	(Sartorius Trainingscenter)			
09:40	Transfer to Sartorius College (from Sartorius Traningscenter)			
10:00 – 10:15	Opening Day 2			
10:15 – 11:00	Manufacturing strategies for patient scale	Dr. Nina G. Bauer, Lonza, Switzerland		
	cell therapies	Assoc. Director of Commercial Development,		
		Autologous Cell Therapies		
11:00 - 11:30	Allogenic approach development by Servier and	Dr. Thierry Wurch, Servier, France		
	the preclinical data of UCART19	Director of External Studies in Immuno-oncology		
11:30 - 12:30	Lunch break Application & Poster Session			
12:30 - 13:00	Small molecules to enable, faciliate and improve	Prof. Dr. Stefan Wölfl University Heidelberg, Germany		
	iPSC generation and cell reprogramming	Institute for Pharmacy and molecular Biotechnology		
13:00 - 13:30	Mesenchymal stem cells in immunotherapy	Dr. Ulf Geumann, apceth Biopharma GmbH, Germany		
		Group Leader Preclinical Development		
13:30 – 14:00	Retroviral and lentiviral production: development and	Dr. Francesca Bellintani, MolMed, Italy		
	scaling up of upstream and downstream process steps	Vector Downstream Process Development Manager		
14:00 – 14:10	Sum up & Closing			

Registration

March 20 – 21, 2018

To register and to obtain further information, please visit our website: promotions.sartorius.com/rxf2018

The registration fee includes admission, gala dinner, all coffee breaks, lunches and the optional plant tour. Advance registration is required.

We offer an early bird discount until January 15, 2018

	Industry Business	Academia	PhD Students Students
Early Bird	395 EUR	295 EUR	105 EUR
Regular	595 EUR	495 EUR	195 EUR
Group Ticket	Pay the 1st ticket and get 50% off for every additional registration		

Venue:

Sartorius College Otto Brenner Strasse 20 37079 Goettingen, Germany www.sartorius.com

Your Contact:

Romi Jeromis Sartorius Lab Instruments GmbH & Co. KG Phone: +49.551.308.2659

forum@Sartorius.com

If you have any questions, just contact us at any time – we would be happy to help you.

Please note that photos and videos will be taken during the event. If you do not wish to be photographed, please let us know upon registration.

Follow us on Twitter #rxf2018



Research Xchange Forum 2018

Get insights into the latest developments from internationally renowned academic and industry speakers.

Special Section:

Lectures from "The Sartorius & Science Prize for Regenerative Medicine & Cell Therapy" Winner and Finalists.







March 20-21, 2018 Register now!

To register and to obtain further information, please visit our website:

promotions.sartorius.com/rxf2018



Sartorius Lab Instruments GmbH & Co. KG Otto-Brenner-Strasse 20 37079 Goettingen